Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin...
Samsung Biologics (KRX: 207940.KS) reported its fourth quarter and full-year 2020 financial results indicating strong business performance,...
Samsung Biologics (207940.KS) set forth its dynamic growth plan for the next decade at the 2021 Annual JP Morgan Healthcare Conference. John Rim,...
Samsung Biologics (KRX: 207940.KS) announced John Rim as its President and CEO. The appointment was made effective immediately and formalized via the ...
Samsung Biologics (KRX: 207940.KS) announced the launch of a virtual showroom to provide key features and real-time construction updates of its...
Samsung Biologics (KRX: 207940.KS) officially began construction of its Plant 4 in Incheon, South Korea. Dubbed the "Super Plant," the new,...
Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies ...
Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality (VR)...
Samsung Biologics Co., Ltd. ("Samsung Biologics") (KRX: 207940.KS) and Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), today announced...
Samsung Biologics (207940.KS) has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an...
At a virtual ceremony today, Samsung Biologics (KRX: 207940.KS) announced the grand opening of its first US CDO R&D Center in San Francisco, bringing ...
Samsung Biologics (KRX: 207940.KS) maintained steady financial results for its fiscal 2020 third quarter ending September 30, demonstrating confident ...
Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full...
Samsung Biologics (207940.KS) has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation...
Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein...
Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement,...
Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat...
Samsung Biologics (KRX: 207940.KS) today held an online press conference to announce its plans to break ground for a fourth plant within this year....
Samsung Biologics (KRX: 207940.KS) today held an online ceremony to announce the launch of its proprietary cell line technology, S-CHOice. S-CHOice...
Samsung Biologics (KRX: 207940.KS) announced today strong financial results for its fiscal 2020 second quarter ending June 30, 2020, maintaining...
Samsung Biologics (207940.KS) announced a plan to expand its Drug Product (DP) capability in line with increasing market demand and to ensure...
Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate...
Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement...
Samsung Biologics (207940.KS) announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week. As the...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.